Eradicating cancer starts with supporting each person and community affected by cancer. This #WorldCancerDay, we recognize the diverse stories and unique experiences behind every diagnosis and stand together in the fight against this disease. Learn how you can help take action: http://spr.ly/6046hyZng #UnitedByUnique
About us
At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. We're hiring! Our organization offers something for everyone, at all stages of careers and from all backgrounds. Let's take on cancer, together. Content reflects information available and is accurate at the time of publication.
- Website
-
http://exactsciences.com
External link for Exact Sciences
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Madison, Wisconsin
- Type
- Public Company
- Specialties
- Precision oncology, Genomic testing, Cancer screening, Genetic testing, and Research and development
Locations
Employees at Exact Sciences
Updates
-
We applaud Congress on the passage of the #MCEDAct. This landmark legislation establishes a Medicare coverage pathway for MCED tests, such as the Cancerguard® test, potentially expanding access to innovative early cancer-detection technologies. Read more: http://spr.ly/6047hHxRZ
-
-
We're celebrating a meaningful milestone ahead of #WorldCancerDay: more than 2 million breast cancer patients worldwide have received personalized care with the Oncotype DX Breast Recurrence Score® test. This means 2 million patients and health care providers were empowered to make confident, informed treatment decisions — guidance that can be life-changing. Every test tells a unique story, and we’re proud to celebrate every patient, provider, and team member who has been part of more than 2 million of them. http://spr.ly/6040hH9F6 #OncotypeDX2Million
-
Randy’s life has been full of adventure. A school teacher in the Peace Corps, a fantasy author, a world traveler, and a proud husband and father, he lived his life to the fullest. Until November 2024, when a late-stage pancreatic cancer diagnosis interrupted that life of magic: “They told me I likely had about 15 months left.” Randy Webster passed away on January 24th, 2026. But his legacy continues. By sharing his story, he hopes for a future where cancers like his are caught earlier – giving families more time, more memories, and more magic together. And with the Cancerguard® test, that future could become reality. Read more: http://spr.ly/6045hEwxc Katie Couric Media
-
-
A new publication in JAMA reveals colorectal cancer is now the #1 cancer killer for people under 50 years. That means early detection and getting screened starting at age 45 is more important than ever. When colorectal cancer is detected early, it may be more treatable, leading to better outcomes. Learn more: http://spr.ly/6045C7EmL
-
-
Today we honor Dr. Martin Luther King Jr., whose life and legacy continue to inspire action towards equality and justice for all. http://spr.ly/6048CqBzG
-
-
Proud to share new insights at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. We're presenting two abstracts that demonstrate how machine learning and claims data can unlock scalable, real-world insights for cancers such as liver and pancreatic, supporting innovative early detection strategies. #GI26
-
As the licensee of Freenome’s CRC blood tests, Exact Sciences is excited to see this new data from Freenome at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. Improving early-stage and precancer detection on CRC blood tests is crucial to ensure the best outcomes for patients who won’t use other screening options. We’re excited to have these blood tests as part of our portfolio, so patients will be able to access the test that’s right for them. #GI26
We’re sharing new data this week at the @ASCO Gastrointestinal Cancers Symposium on the clinical performance of an updated version of Freenome’s SimpleScreen™ CRC screening blood test. In a large head-to-head case-control validation study, the updated test showed meaningful performance improvements over the first-generation assay, with CRC sensitivity at 85% and APL sensitivity at 22%. These advances reflect targeted upgrades across the assay, workflow, and automation, and reinforce the strength of Freenome’s multiomics discovery platform. These results build on the PREEMPT CRC Study and support our approach to systematically improving early cancer detection through thoughtful versioning of our technology. If you’re attending ASCO GI, stop by our poster session on Saturday, Jan. 10, at 7 am PT, to see the full data and learn more. Read the press release here: https://lnkd.in/gaNt3EjF #GI26 #EarlyCancerDetection #ColorectalCancer #CancerScreening #BloodBasedTesting #Multiomics
-